| Schizophrenia
Igalmi vs Latuda
Side-by-side clinical, coverage, and cost comparison for schizophrenia.Deep comparison between: Igalmi vs Latuda with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLatuda has a higher rate of injection site reactions vs Igalmi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Latuda but not Igalmi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Igalmi
Latuda
At A Glance
Sublingual or buccal film
As needed (acute use)
Alpha-2 adrenergic receptor agonist
Oral
Once daily
Atypical antipsychotic
Indications
- Schizophrenia
- Bipolar I disorder
- Bipolar Disorder Type 2
- Schizophrenia
- Depression, Bipolar
Dosing
Schizophrenia, Bipolar I disorder, Bipolar Disorder Type 2 - Adults Mild or moderate agitation: 120 mcg initial dose SL or buccal; severe agitation: 180 mcg initial; up to 2 additional doses (60-90 mcg) at least 2 hours apart; maximum 240-360 mcg/day.
Mild or Moderate Hepatic Impairment Mild or moderate agitation: 90 mcg initial; severe agitation: 120 mcg initial; optional additional doses of 60 mcg at least 2 hours apart; maximum 210-240 mcg/day.
Severe Hepatic Impairment Mild or moderate agitation: 60 mcg initial; severe agitation: 90 mcg initial; optional additional doses of 60 mcg at least 2 hours apart; maximum 180-210 mcg/day.
Geriatric Patients (>=65 years) 120 mcg initial dose regardless of agitation severity; optional additional doses of 60 mcg at least 2 hours apart; maximum 240 mcg/day.
Schizophrenia Adults: 40 mg once daily (range 40-160 mg/day); adolescents 13-17 years: 40 mg once daily (range 40-80 mg/day); take with food (at least 350 calories).
Depression, Bipolar Adults: 20 mg once daily as monotherapy or adjunctive therapy with lithium or valproate (range 20-120 mg/day); pediatric patients 10-17 years: 20 mg once daily as monotherapy (range 20-80 mg/day); take with food (at least 350 calories).
Contraindications
—
- Known hypersensitivity to lurasidone HCl or any components in the formulation
- Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil)
- Concomitant use with strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. John's wort, phenytoin, carbamazepine)
Adverse Reactions
Most common (>=5%) Somnolence, oral paresthesia or oral hypoesthesia, dizziness, dry mouth, hypotension, orthostatic hypotension.
Serious Hypotension, orthostatic hypotension, bradycardia, QT interval prolongation, somnolence, withdrawal reactions, tolerance and tachyphylaxis.
Postmarketing Arrhythmia, atrial fibrillation, cardiac arrest, bradycardia, convulsion, apnea, bronchospasm, agitation, delirium, hallucination, hypertension, rash, urticaria.
Most common (>=5%) Somnolence, akathisia, extrapyramidal symptoms, nausea, vomiting, diarrhea, anxiety
Serious Neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes, cerebrovascular adverse reactions, hyperprolactinemia, leukopenia/neutropenia/agranulocytosis, orthostatic hypotension and syncope, seizures, body temperature dysregulation
Postmarketing Urticaria, throat swelling, tongue swelling, dyspnea, rash, hyponatremia
Pharmacology
Dexmedetomidine is an alpha-2 adrenergic receptor agonist whose mechanism of action in acute agitation is thought to involve activation of presynaptic alpha-2 adrenergic receptors; it also exhibits concentration-dependent QT prolongation.
Lurasidone is an atypical antipsychotic that acts as an antagonist at dopamine D2 and serotonin 5-HT2A and 5-HT7 receptors and as a partial agonist at 5-HT1A receptors, with little affinity for histamine H1 or muscarinic M1 receptors; its efficacy in schizophrenia and bipolar depression may be mediated through combined D2 and 5-HT2A receptor antagonism.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Igalmi
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (11/12)
Latuda
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (1/12)
UnitedHealthcare
Igalmi
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (1/8) · Qty limit (0/8)
Latuda
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Igalmi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (1/3)
Latuda
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Igalmi.
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
IgalmiView full Igalmi profile
LatudaView full Latuda profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.